Layla R. Hilbun

Suggest Changes
Learn More
e13521 Background: Sorafenib had demonstrated single agent activity in non-small cell and small cell lung cancer. METHODS A non-comparative, two arm phase I trial escalating sorafenib in(More)
  • 1